SLC5A2 and diabetic cardiomyopathy: For example, SGLT2 inhibitors can protect against diabetic cardiomyopathy and myocardial fibrosis through suppressing fibroblast activation and endothelial to mesenchymal transition via AMPKα-mediated inhibition of transforming growth factor β/Smad signaling (Li et al., 2019; Tian et al., 2021).